Estrogen with interrupted progestin HRT: A review of experimental and clinical studies

Maturitas

Volumn 34, Issue 2, 2000, Pages 97-108

  Casper, Robert F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breakthrough bleeding; Estrogen receptors; Hormonal replacement therapy; Interrupted progestin; Progestin receptors

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; GONADORELIN AGONIST; NORETHISTERONE; NORGESTIMATE;

BREAST CANCER; CORONARY ARTERY DISEASE; DEPRESSION; DRUG SAFETY; DRUG SENSITIVITY; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESTROGEN ACTIVITY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; IRRITABILITY; LIPID METABOLISM; MENOPAUSE; NONHUMAN; PATIENT COMPLIANCE; RECEPTOR BINDING; RECEPTOR DENSITY; REVIEW; RISK ASSESSMENT;

EID: 0033959369     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(99)00076-6     Document Type: Article

References (66)

1. Samsioe G. Osteoporosis - an update. Acta Obstet. Gynecol. Scand. 76:1997;189-199.
2. Grodstein F., Stampfer M.J. Cardiovascular disease: impact of sex steroid replacement. Adashi E.Y., Rock J.A., Rosenwaks Z. Reproductive Endocrinology, Surgery, and Technology. 1996;1851-1866 New York, Lippencott-Raven Publishers.
3. Fernandez E., La Vecchia C., Braga C. et al. Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol. Biomarkers Prevent. 7:1998;329-333.
4. Yaffe K., Sawaya G., Lieberburg I. et al. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. J. Am. Med. Assoc. 279:1998;688.
5. Cauley J.A., Cummings S.R., Black D.M. et al. Prevalence and determinants of oestrogen replacement therapy in elderly women. Am. J. Obstet. Gynecol. 163:1990;1438-1444.
6. Nachtigall L.E. Enhancing patient compliance with hormone replacement therapy at the menopause. Obstet. Gynecol. 75(Suppl):1990;77S-80S.
7. Wilkes H.C., Meade T.W. Hormone replacement therapy in General Practice. Br. Med. J. 302:1991;1317-1320.
8. Wren B.G., Brown L. Compliance with hormone replacement therapy. Maturitas. 13:1991;17-21.
9. Ravnikar V.A. Compliance with hormone replacement therapy: Are women receiving the full impact of hormone replacement therapy preventative health benefits? Womens Health Issues. 2:1992;75-80.
10. Casper R.F. Compliance problems with hormone replacement. J. Soc. Obstet. Gynaecol. Can. 14:1992;43-45.
11. Walsh J.M.E., Brown J.S., Rubin S. et al. Postmenopausal hormone therapy: factors influencing women's decision making. Menopause. 4(1):1997;39-45.
12. Samsioe G. Hormone replacement therapy: aspects of bleeding problems and compliance. Int. J. Fertil. Menopausal Stud. 41(1):1996;11-15.
13. Rozenberg S., Vandromme J., Kroll M. et al. Compliance to hormone replacement therapy. Int. J. Fertil. Menopausal Stud. 40(Suppl 1):1995;23-32.
14. Griffiths F., Convery B. Women's use of hormone replacement therapy for relief of menopausal symptoms, for prevention of osteoporosis and after hysterectomy. Br. J. Gen. Pract. 45(396):1995;355-358.
15. Stumpf P.G., Trolice M.P. Compliance problems with hormone replacement therapy. Obstet. Gynecol. Clin. NA21(2):1994;219-229.
16. Doren M, Schneider HP. The impact of different HRT regimens on compliance. Int J Fertil Menopausal Stud 1996;41(1):29-39.
17. Beresford S.A., Weiss N.S., Voigt L.F., McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet. 349:1977;458-461.
18. Cushing K.L., Weiss Voigt L.F., McKnight B., Beresford S.A. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens. Obstet. Gynecol. 91:1998;35-39.
19. Effects of hormonal replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. J. Am. Med. Assoc. 275:1996;370-375.
20. Woodruff J.D., Pickar J.H. Incidence of endometril\al hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The menopause study group. Am. J. Obstet. Gynecol. 170:1994;1213-1223.
21. Hulka B.S., Kaufman D.G., Fowler W.C. Jr et al. Predominance of early endometrial cancers after long-term estrogen use. J. Am. Med. Assoc. 244:1980;2419-2422.
22. Collins J.A., Allen L.H., Donner A., Adams O. Oestrogen use and survival in endometrial cancer. Lancet. 2:1980;961-964.
23. Elwood J.M., Boyes D.A. Clinical and pathological features and survival of endometrial cancer patients in relation to prior use of estrogens. Gynecol. Oncol. 10:1980;173-187.
24. Evan G., Harrington E., Fanidi A. et al. Integrated control of cell proliferation and cell death by the c-myc oncogene. Phil. Trans. R. Soc. London B. 345:1994;269-275.
25. Clarke C.L., Sutherland R.L. Progestin regulation of cellular proliferation. Endocrine Rev. 11:1990;266-301.
26. Dupont W.D., Page D.L. Menopausal estrogen replacement therapy and breast cancer. Arch. Int. Med. 151:1991;67-72.
27. King R.J.B. Progression from steroid sensitive to insensitive state in breast tumours. Cancer Surveys. 14:1992;131-146.
28. Gelber R.D., Cole B.F., Goldhirsch A. et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet. 347:1996;1066-1071.
29. Holli K., Isola J., Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J. Clin. Oncol. 16:1998;3115-3120.
30. Schairer C., Gail M., Byrne C. et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J. Natl. Cancer Inst. 91:1999;264-270.
31. Salmon R.J., Ansquer Y., Asselain B., Languille O., Lesec G., Remvikos Y. Clinical and biological characteristics of breast cancers in post- menopausal women receiving hormone replacement therapy for menopause. Oncol. Rep. 6:1999;699-703.
32. Willis D.B., Calle E.E., Miracle-McMahill H.L., Heath C.W. Jr Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States [see comments]. Cancer Causes Control. 7:1996;449-457.
33. Henderson B.E., Paganini-Hill A., Ross R.K. Decreased mortality in users of estrogen replacement therapy. Arch. Intern. Med. 151:1991;75-78.
34. Bergkvist L., Adami H.O., Persson I. et al. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am. J. Epidemiol. 30:1989;221-228.
35. Gambrell R.D. Jr, Massey F.M., Castaneda T.A. et al. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet. Gynecol. 55:1980;732-738.
36. Noe M., Kunz G., Herbertz M., Mall G., Leyendecker G. The cyclic pattern of the immunocytochemical expression of oestrogen and progesterone receptors in human myometrial and endometrial layers: characterization of the endometrial-subendometrial unit. Hum. Reprod. 14:1999;190-197.
37. Moutsatsou P., Sekeris C.E. Estrogen and progesterone receptors in the endometrium. Ann. N.Y. Acad. Sci. 816:1997;99-115.
38. West N.B., Brenner R.M. Progesterone-mediated suppression of estradiol receptors in cynomolgus macaque cervix, endometrium and oviduct during sequential estradiol-progesterone treatment. J. Steroid Biochem. 22:1985;29-37.
39. Whitehead M.I., Townsend P.T., Pryse-Davies J. et al. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. New Engl. J. Med. 305:1981;1599-1605.
40. Ace C.I., Okulicz W.C. Differential gene regulation by estrogen and progesterone in the primate endometrium. Mol. Cell. Endocrinol. 115:1995;95-103.
41. Silferstolpe G., Gustafson S., Samsioe G. Lipid metabolic studies in oophorectomized women: effects on serum lipids and lipoproteins of three synthetic progestogens. Maturitas. 4:1982;103-111.
42. Ottosson U.B. Oral progesterone and estrogen/progestogen therapy. Effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins. Acta Obstet. Gynecol. Scand. 127(Suppl):1984;1-57.
43. Tikkanen M.J., Nikkila E.A., Kuusi T., Sipinen S. Reduction of plasma high-density lipoprotein-2 cholesterol and increase of postheparin plasma hepatic lipase activity during progestin treatment. Clin. Chim. Acta. 115:1981;63-71.
44. Haffner S.M., Kushwaha R.S., Foster D.M. et al. Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. Metabolism. 32:1983;413-420.
45. Phillips A., Hahn D.W., McGuire J.L. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity. Am. J. Obstet. Gynecol. 167:1992;1191-1196.
46. Adams M.R., Clarkson T.B., Shively C.A. et al. Oral contraceptives, lipoproteins, and atherosclerosis. Am J Obstet Gynecol. 163:1990;1388-1393.
47. Hammarback S., Backstrom T., Holst J., von Schoultz B., Lyrenas S. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progesterone post-menopausal replacement therapy. Acta Obstet. Gynecol. Scand. 64:1985;393-397.
48. Zou K., Ing N.H. Oestradiol upregulates oestrogen receptor, cyclophilin, and glyceraldehyde phosphate dehydrogenase mRNA concentrations in endometrium, but down-regulates them in liver. J. Steroid Biochem. 64:1998;231-237.
49. Ing N.H., Ott T.L. Estradiol up-regulates estrogen receptor-alpha messenger ribonucleic acid in sheep endometrium by increasing its stability. Biol. Reprod. 60:1999;134-139.
50. Leavitt W.W., Okulicz W.C., McCracken J.A. et al. Rapid recovery of nuclear estrogen receptor and oxytocin receptor in the ovine uterus following progesterone withdrawal. J. Steroid Biochem. 22:1985;686-691.
51. Okulicz W.C., Balsamo M., Tast J. Progesterone regulation of endometrial estrogen receptor and cell proliferation during the late proliferative and secretory phase in artificial menstrual cycles in the rhesus monkey. Biol. Reprod. 49:1993;24-32.
52. Casper R.F., MacLusky N.J., Vanin C., Brown T.J. Rationale for estrogen with interrupted progestin as a new low-dose hormonal replacement therapy. J. Soc. Gynecol. Invest. 3(5):1996;225-234.
53. McGinnis M.Y., Krey L.C., MacLusky N.J., McEwen B.S. Steroid receptor levels in intact and ovariectomized estrogen-treated rats: an examination of quantitative, temporal and endocrine factors influencing the efficacy of an estradiol stimulus. Neuroendocrinology. 33:1981;158-165.
54. Vanin C.M., MacLusky N.J., Grynpas M.D., Casper R.F. The effect of three hormone replacement regimens on bone density in the aged oophorectomized rat. Fertil. Steril. 63:1995;643-651.
55. Shupnik M.A., Gordon M.S., Chin W.W. Tissue-specific regulation of rat estrogen receptor mRNAs. Mol. Endocrinol. 3:1989;660-665.
56. Okulicz W.C., Evans R.W., Leavitt W.W. Progesterone regulation of the occupied form of nuclear estrogen receptor. Science. 213:1981;1503-1505.
57. Leavitt W.W., Cobb A.D., Takeda A. Progesterone-modulation of estrogen action: rapid down regulation of nuclear acceptor sites for the estrogen receptor. Adv. Exp. Med. Biol. 230:1987;49-78.
58. Yamashita S. Localization and functions of steroid hormone receptors. Histol. Histopathol. 13:1998;255-270.
59. Zheng J., Johnson M.L., Redmer D.A., Reynolds L.P. Estrogen and progesterone receptors, cell proliferation, and c-fos expression in the ovine uterus during early pregnancy. Endocrinology. 137:1996;340-348.
60. Phillips A., Demarest K., Hahn D.W. et al. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception. 41:1990;399-410.
61. Brenner P.F. The pharmacology of progestogens. J. Reprod. Med. 27:1982;490-497.
62. Vanin C., MacLusky N.J., Chachra D. et al. Lumbar vertebral density and mechanical properties in aged ovariectomized rats treated with estrogen and norethinedrone or norgestimate. Am. J. Obstet. Gynecol. 173:1995;1491-1498.
63. Chacras D., Vanin C., MacLusky N. et al. The effect of different hormone replacement therapy regimens on the mechanical properties of rat vertebrae. Calcif. Tis. Int. 56:1995;130-134.
64. Kasra M., Vanin C.M., MacLusky N.J. et al. Effects of different estrogen and progestin regimens on the mechanical properties of rat femur. J. Orthop. Res. 15:1997;118-123.
65. Casper R.F., Chapdelaine A. Estrogen and interrupted progestin: a new concept for menopausal hormone replacement therapy. Am. J. Obstet. Gynecol. 168:1993;1188-1196.
66. Cameron S.T., Critchley H.O.D., Glasier A.F. et al. Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women. Br. J. Obstet. Gynaecol. 104:1997;1184-1190.